Case Note & Summary
The dispute arose between two pharmaceutical companies, Cadila Healthcare Limited and Cadila Pharmaceuticals Limited, regarding the use of the trade mark 'Falcitab' by the respondent, which the appellant claimed was confusingly similar to its own trade mark 'Falcigo'. Both companies had taken over the assets of the erstwhile Cadila Group under a restructuring scheme, which allowed them to use the name 'CADILA'. The appellant's drug, Falcigo, was registered with the Trade Marks Registry in 1996 and was used for treating cerebral malaria, while the respondent's drug, Falcitab, was approved for use in 1997. The appellant filed a suit for injunction against the respondent in the District Court at Vadodara, arguing that the similarity in names would lead to confusion among consumers. The respondent defended its position by stating that 'Falci' was derived from 'Falcipharum Malaria', a common practice in the pharmaceutical industry. The District Court dismissed the appellant's application for an interim injunction, concluding that the two drugs differed significantly in appearance, formulation, and pricing, and were sold exclusively to hospitals, minimizing the risk of consumer confusion. The High Court upheld this decision, finding no likelihood of confusion. Upon appeal to the Supreme Court, the court declined to interfere with the lower courts' orders, citing the need for a thorough examination of evidence on the merits of the case and directed for an expedited trial of the suit. The court reiterated the principles governing passing off actions, emphasizing the importance of assessing the overall similarity of trade marks and the context in which they are used, particularly in the pharmaceutical sector where consumer safety is paramount. The court noted that the potential for confusion in medicinal products necessitates a higher standard of scrutiny due to the serious implications of misidentification. Ultimately, the court upheld the lower courts' findings, emphasizing that the appellant had not demonstrated a likelihood of confusion sufficient to warrant an injunction.
Headnote
A) Trade Marks - Passing Off - Likelihood of Confusion - Trade Marks Act, 1999, Sections 27, 28 - The court held that the appellant failed to establish a likelihood of confusion between the trade marks 'Falcitab' and 'Falcigo', as both products were Schedule L drugs sold only to hospitals, thus reducing the chance of consumer confusion. The court emphasized the need for a careful examination of the overall similarity of the marks in the context of the products' nature and intended consumers (Paras 1-16).
Issue of Consideration
Whether the use of the trade mark 'Falcitab' by the respondent was likely to cause confusion with the appellant's trade mark 'Falcigo'.
Final Decision
The Supreme Court upheld the dismissal of the injunction application, affirming that the appellant did not demonstrate a likelihood of confusion between the trade marks 'Falcitab' and 'Falcigo'. The court directed for an expedited trial of the suit, emphasizing the need for careful consideration of evidence on the merits.
Law Points
- Trade Marks Act
- passing off
- likelihood of confusion
- registered trade mark
- unregistered trade mark
- exclusive rights
- pharmaceutical products
